Premium
Estrogen replacement therapy and risk of lung cancer
Author(s) -
Blackman Janine A.,
Coogan Patricia F.,
Rosenberg Lynn,
Strom Brian L.,
Zauber Ann G.,
Palmer Julie R.,
Langenberg Patricia,
Shapiro Samuel
Publication year - 2002
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.733
Subject(s) - medicine , lung cancer , odds ratio , estrogen , logistic regression , epidemiology , estrogen receptor , oncology , confidence interval , hormone replacement therapy (female to male) , cancer , breast cancer , gynecology , testosterone (patch)
Purpose Some epidemiological data suggest that sex hormones may influence lung cancer risk, and estrogen receptors have been found in human non‐small cell lung tumors. We assessed the relation of the use of estrogen replacement therapy (ERT) to the risk of lung cancer in our hospital‐based Case–Control Surveillance Study, conducted in four US centers during 1976 to 2001. Methods Cases were 662 women aged 40 through 74 years with lung cancer and controls were 4671 women admitted for conditions unrelated to ERT use. We used multivariate unconditional logistic regression models to estimate odds ratios (OR) and 95% confidence intervals (CI) for ERT use for at least 3 months compared to no use or use for less than 3 months. Results The OR for lung cancer among ERT users was 1.0 (95%CI 0.8–1.4), and it was 1.0 (95%CI 0.7–1.4) among users of conjugated estrogens only. Risk did not increase as the duration of use increased. Odds ratios for specific lung cancer cell types were not significantly increased or decreased for use of ERT or conjugated estrogens. There were non‐significant increases for non‐small cell types other than squamous, but there was no consistent pattern across duration of use. Conclusion Our data do not support an increased risk of lung cancer among women who use ERT. Copyright © 2002 John Wiley & Sons, Ltd.